This article was originally published in The Gray Sheet
Executive SummaryAcquires 1 mil. of Oncometrics Imaging Corp. common stock from Xillix Technologies Corp., making Oncometrics a wholly owned subsidiary of AccuMed. Xillix divested its Oncometrics stock in order to focus on developing its LIFE fluorescent endoscopy system platform for the early detection and localization of cancer. Terms of the transaction were not disclosed
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.